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ABSTRACT
Visual hallucinations (VH) occur commonly in Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB) but
are reported much less frequently in other
neurodegenerative causes of parkinsonism, such as
progressive supranuclear palsy, multiple system atrophy
and corticobasal degeneration syndrome. This clinical
sign may be helpful when considering the differential
diagnosis of patients with parkinsonism. The observation
that VH may be speciﬁc to Lewy body pathology
probably reﬂects a greater vulnerability of the visual
systems to PD and DLB neurodegeneration compared
with other diseases. Topographic differences in
pathology are probably the major factor producing VH in
Lewy body diseases, rather than neurophysiological
changes that are speciﬁc to a-synuclein protein
accumulation. VH correlate with pathology in the limbic
system and more speciﬁcally the amygdale that is
frequently affected in PD and DLB but relatively
preserved in other forms of parkinsonism often
misdiagnosed as PD. In this review, the published
frequencies of VH in these different conditions are
compared to put into context the notion of VH as
a clinical clue to underlying Lewy body pathology.
INTRODUCTION
Parkinsonism is a clinical syndrome deﬁned by the
presence of bradykinesia with tremor, extrapyra-
midal rigidity and postural instability. Progressive
neurodegenerative parkinsonism is most
commonly associated with idiopathic Parkinson’s
disease (PD) but is also a clinical feature in
progressive supranuclear palsy (PSP), multiple
system atrophy (MSA) and vascular parkinsonism
among other nosological entities. Over the past
2 decades, operational diagnostic criteria have been
developed for these conditions which appears to
have improved diagnostic accuracy.
1 Even so, it is
common for patients to partially satisfy several
different diagnostic criteria forcing clinicians to
consider other factors outside these criteria when
reaching a clinical diagnosis. In specialist move-
ment disorder clinics the clinical diagnosis may be
incorrect in up to 15% of patients compared with
pathological diagnosis post mortem.
2 This inac-
curacy is even more apparent early in disease when
clinical signs have yet to fully evolve and parkin-
sonian features are mild.
3e5 Accurate diagnosis is
important for informing the patient about their
disease and prognosis, planning treatment stra-
tegies and, in the future, for testing possible
neuroprotective treatments.
While parkinsonian motor features are commonly
the instigator for a patient to attend medical
services, non-motor features may be present which
assist in the differential diagnosis. Visual hallucina-
tions (VH) are a common ﬁnding in patients with
underlying Lewy body pathology (PD and dementia
with Lewy bodies (DLB)) but are not frequently
associated with other parkinsonian diseases. This
observation has prompted the consideration that
VH be included among the clinical factors predictive
of Lewy body pathology.
In this context, VH may provide a clinical clue
that assists in the diagnosis of patients presenting
with inconclusive clinical signs and atypical
parkinsonism, or may help predict the underlying
pathology or anatomical distribution of that
pathology.
CLINICAL PHENOMENOLOGY AND DIFFERENTIAL
DIAGNOSIS
Hallucinations are sensory perceptions in the
absence of an external stimulus and may manifest
as visual, auditory, olfactory or tactile phenomena.
In comparison, illusions are distortions of percep-
tion in the presence of an external stimulus.
Hallucinations occur in 15e75% of patients with
PD.
6e10 The variability in reported prevalence
depends in part on study methodology. Most
published reports included patients referred to
specialist movement disorders clinics and report
hallucinations in between 25% and 50% of all PD
patients.
67In contrast, a community survey of
a geographically deﬁn e dc o h o r ti nN o r w a yw i t hc a s e
ascertainment of 96% revealed a much lower rate of
reported hallucinations of 16%.
8 Longitudinal studies
have reported a higher prevalence than cross sectional
studies, increasing over the course of the disease.
10 11
PD was originally described in terms of motor
disturbance but non-motor features, including
cognitive and mood disturbances, sleep disturbance,
constipation and anosmia, are prominent and may
predate the onset of motor symptoms by up to
10 years.
12 Other parkinsonian diseases often
present with the same motor features and clues to
alternative diagnoses may remain obscured for
some months or years. PSP, MSA and corticobasal
degeneration (CBD) are often misdiagnosed as PD
or DLB early in their course because of this.
The clinical signs of PD are usually asymmetric in
onset, often with rest tremor, and a good response
to dopaminergic medications is expected. The
pathology is characterised by nigrostriatal deﬁciency
with neuronal loss predominantly in the substantia
nigra pars compacta, among other brainstem nuclei,
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Movement disorderswith accumulation of a-synuclein in Lewy bodies and neurites.
DLB is used to designate patients with dementia and parkin-
sonism that occur together.
13 The pathological difference
between DLB and PD can be subtle and relates to the distribution
of synuclein pathology and the extent of neuronal loss.
14
In contrast, PSP is characterised by prominent akinesia,
impaired postural reﬂexes, falls and vertical supranuclear gaze
palsy or slowing of vertical saccades. These symptoms do not
improve with dopaminergic medications. PSP is a primary
tauopathy with neuroﬁbrillary degeneration most severe in the
globus pallidus, subthalamic nucleus, substantia nigra and pons.
Up to a third of patients with PSP tau pathology have other
clinical presentations, including: PSPeparkinsonism (PSP-P)
with dominant early features of asymmetry, tremor, bradyki-
nesia, dystonia and levodopa responsiveness; and pure akinesia
with gait freezing characterised by early gait freezing without
rigidity, tremor, dementia or supranuclear gaze palsy, which is
somewhat less common.
15 16
The ‘motor presentation’ of CBD manifests as unilateral limb
rigidity, dystonia and bradykinesia with myoclonus and cortical
sensory loss emerging later. This non-levodopa responsive
parkinsonism may coexist with frontal and parietal cognitive
disturbance with features that include apathy, agitation,
personality change, depression, apraxia and a non-ﬂuent aphasia.
Pathologically there are diffuse cortical neuronal and glial tau
deposits in addition to swollen or ‘ballooned’ neurons.
17
Patients with MSA experience symptomatic dysautonomia,
cerebellar ataxia, pyramidal signs and parkinsonism that is usually
poorly responsive to levodopa. Neuropsychiatric features are seen
in many cases, predominantly depression in more than 40%, but
dementia is uncommon. Neuronal loss, reactive gliosis and iron
deposition are seen in the basal ganglia, pons, medulla, cerebellum,
inferior olivary nucleus and spinal cord.
18
HALLUCINATIONS IN PARKINSON’S DISEASE
Visual experiences account for the majority of hallucinations in
PD and DLB, and only a small proportion of patients report
auditory, tactile or olfactory hallucinations.
6 Most authors have
focused on the appearance of formed VH which are predomi-
nantly of people, animals or objects. These are generally
described as solid images which may be still or moving, and may
be miniaturised in up to 35% of cases.
19 One-third of patients
report hallucinations lasting for hours at a time.
19
A prodromal syndrome of minor hallucinations probably
precedes the emergence of formed VH. These brief experiences
include visual illusions, extracampine hallucinations (or ‘pres-
ence’ hallucinations, the sense of a presence in the room, often
behind or beside the patient) or passage hallucinations (sense of
movement in the periphery).
6 These experiences are often not
reported by patients as hallucinations, and must be sought on
direct questioning.
20 The majority of patients report that
hallucinations appear when they have their eyes open, particu-
larly in dim lighting or at the end of the day.
Most patients are aware of the hallucinatory nature of their
experiences, with insight maintained in all non-demented and
64% of demented patients in one series.
6 They are often not
perceived as frightening, although when they do become so the
behavioural disturbance that may ensue is likely to have
signiﬁcant impact on care needs and are likely the explanation
for the signiﬁcant contribution of hallucinations to the rate of
nursing home placement.
21 The presence of hallucinations
correlates with the incidence of major depression,
22 and are
associated with increasing age,
7 sleep disturbance,
7 depression
19
and cognitive disturbance.
7
The relationship between VH and dopaminergic medications
in PD is complex. VH were occasionally reported in PD before
the availability of dopaminergic medication.
23 Conﬂicting
reports have shown both a positive
24 and no association
between dopaminergic medication dose and the appearance
of VH.
67Most medications used in the treatment of PD,
including dopaminergic, anticholinergic and monoamine oxidase
inhibitors, may also induce delirium.
24
In one retrospective series, eight patients developed halluci-
nations in the setting of dopamine agonist use for pituitary
tumours which translated to a rate of 1% in that series of 600
patients.
25 The hallucinations reported were predominantly
auditory and associated with paranoid delusions and all patients
had resolution of their psychotic symptoms with reduction or
withdrawal of the medication. This suggests that while dopa-
minergic medication may have some inherent hallucinatory
potential, the much higher rate of hallucinations seen in
parkinsonian patients implies hallucinations develop as part of
the disease process.
9
VISUAL HALLUCINATIONS AS A MARKER OF DISEASE
PROGRESSION
In contrast to DLB, VH are uncommon early in PD and appear
to be the most important risk factor for permanent placement in
a nursing home and associated increased mortality.
21
The proposed pathological staging of PD by Braak
26 suggests
synuclein pathology begins in the brainstem and progresses in
a caudal-rostral pattern to the pons and mesencephalon. Non-
motor symptoms such as REM sleep behaviour disorder and
hyposmia have been suggested to relate to the involvement of
these brainstem structures rather than dopaminergic cell loss
and commonly predate motor features.
12 Motor dysfunction
progresses in parallel to nigrostriatal dopaminergic deﬁciency, as
assessed by functional imaging over the course of the disease.
27
Lewy body density correlates directly with disease duration
28
and with dementia
29 and is therefore predicted to evolve
throughout the disease, with inevitable involvement of the
cortex. Longitudinal studies show a progressive increase in
cumulative prevalence of dementia over the course of the
disease
10 11 and coincident development of hallucinations.
6
VH have been suggested as a marker of disease severity and
a measure of disease progression, which corresponds to standard
clinical measures of disease severity.
7 Duration of disease appears
to correlate most closely with the development of hallucina-
tions,
6 and time to ﬁrst hallucination is reported to be about
12 years after diagnosis.
9
DOES THE APPEARANCE OF VISUAL HALLUCINATIONS
SUGGEST ANATOMICOPATHOLOGICAL CORRELATES?
VH probably emerge as the result of disruptions in several
different brain regions important in visual perception, processing
and interpretation. They have been shown to emerge due to
lesions along the whole of the visual axis, from cortical lesions,
including occipital, temporal, parietal and frontal lobes, as well
as following disruption to deep nuclei and brainstem structures.
The complex relationships between the different pathophysio-
logical factors involved in VH are incompletely understood but
have been nicely integrated in a single model reviewed by
Diederich et al.
30
In the context of PD, where brainstem pathology probably
develops before cortical pathology, the concept of ‘peduncular
hallucinosis’ is of interest. It has been postulated that structural
lesions in the brainstem and its connections (including the
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Movement disordersthalamus and temporal cortex) may cause hallucinations from
disruption of serotonergic inhibitory neurons originating in the
raphe nucleus.
31 These connections are important for regulation
of REM sleep cycles and the resultant loss of inhibition in the
lateral geniculate nucleus could lead to brief dream-like periods
emerging during wakefulness.
32
Sleep disturbance is common in PD and has been related to
the development of hallucinations
7 but the underlying mecha-
nism for this association is unclear. Patients with PD and
hallucinations have reduced sleep efﬁciency and decreased REM
sleep compared with those without.
33 One model of hallucina-
tions that appears relevant to PD is narcolepsy associated
hypnogogic hallucinations which are potentiated by drowsiness
and may be induced by lesions of the brainstem or hypothal-
amus.
34 In PD, brainstem pathology may lead to both sleep
disturbance and hallucinatory phenomena through disruption of
the balance between serotonergic and cholinergic inputs to the
lateral geniculate nucleus of the thalamus, involved in both
arousal and modulation of inputs to the visual cortex.
34 VH
occur earlier and more frequently in patients with DLB
compared with PD, which may be related to the greater
cholinergic deﬁcit in DLB. Cholinergic neuronal loss is prom-
inent in the temporal cortex, striatum and pedunculopontine
projections to the thalamus and is also a feature of PD with
dementia.
35
Disruption to the visual pathway is a well documented
mechanism for producing VH without psychosis, the classic
description of the Charles Bonnet syndrome. This syndrome
describes complex VH with retained insight to the hallucinatory
nature of the visual phenomena in the context of decreased
visual input. VH may emerge following lesions causing loss of
function in the occipital cortex,
36 optic chiasm, optic radiation
and retina.
37 This has been postulated as a central release
phenomena, in which lack of sensory stimulus, or deaf-
ferentation, leads to neuronal hyperexcitability.
38 Evidence to
support this theory includes the demonstration of spontaneous
electrical activity in neurally isolated cortex on EEG and path-
ological studies of deafferented neural tissue.
38
Visual disturbance and problems with visual processing deﬁ-
ciency occur at several different levels in PD so there are several
disease factors that could allow hallucinations to emerge. For
example, disruption of retinal dopamine function in PD under-
lies altered spatial contrast sensitivity which reduces the ability
to undertake visuospatial tasks.
39 Delays in visual evoked
responses and disturbances of visuospatial processing, suggesting
involvement of the visual pathway beyond the retina, have also
been demonstrated in PD.
40 Visual event related potentials are
slower in patients with PD who have reported VH, consistent
with a role for visual processing pathways in their onset.
41
Interestingly, visuospatial functions appear to be relatively
spared in MSA and PSP, where hallucinations are rare.
42
The theoretical models of VH are, to some extent, supported
by imaging and pathological examination. Using MRI voxel
based morphometry, reduced brain volume in the lingual gyrus
and superior parietal cortex in non-demented PD hallucinators
compared with PD non-hallucinators has been reported.
43 These
brain regions contribute to the processing of colour perception
and visuospatial working memory, with dysfunction postulated
to effect visuoperceptive impairments.
43 Although atrophic
changes such as these are indicative of neuronal cell loss,
neuronal dysfunction is likely to be present years before
demonstrable tissue loss occurs. Functional imaging has the
potential to demonstrate in vivo dysfunction and several authors
have used functional imaging in an attempt to identify the
pathological substrate that contributes to hallucinations. Some
of the functional imaging studies have been contradictory
44 45
but some correlate with anatomical predictions.
46 For example,
reduced glucose metabolism shown on ﬂuorodeox-
yglucoseepositron emission tomography in the ventral right
temporal lobe and the right lateral visual cortex in PD suggests
a functional deﬁcit.
46 Pathological investigation of these regions
studying Lewy body density identiﬁed a strong correlation
between VH and pathological severity, particularly medial
temporal lobe Lewy body density.
47 In addition, there is an
association between a-synuclein pathology in the amygdala and
hallucinations in demented PD patients.
48
The limbic system is progressively affected by PD pathology
throughout the course of the disease
28 but is affected early in
DLB. Lewy body pathology preferentially affects the central,
accessory cortical and basolateral nuclei in the amygdala.
48 The
cortical nucleus is involved in olfactory perception and inter-
ruption promotes anosmia, well documented in PD.
12 The
central nucleus projects to brainstem structures and the basal
forebrain, consistent with a role in autonomic functions. The
basolateral nucleus projects to the hippocampus and prefrontal
association cortex, and has a role in modulating consolidation of
emotional memory.
49 Increased Lewy bodies in the basolateral
nucleus has been correlated with the presence of VH in those
with PD.
48 The amygdala has a pivotal role in the recognition of
facial expressions
50 and integration of the ventral visual system
subserving conscious visual identiﬁcation.
51 In non-demented
PD patients increased Lewy body density in the amygdala
predicted the development of hallucinations, with the highest
correlation occurring with basolateral nucleus pathology.
47 48
Models of the visual systems propose that the amygdala is
responsible for integrating emotional responses to visual stimuli
in the extrageniculostriate or ‘ventral’ visual system.
50 The
amygdala receives sensory inputs from temporal and thalamic
regions, and projects to temporal, occipital and brainstem
structures that are important in the control of behavioural
responses. It is proposed that the amygdala modulates behaviour
through adjustments of neuronal activity in the extrastriate
cortex in response to the emotional content of visual input.
Interruption of amygdalar function from progressive a-synuclein
neurodegeneration may lead to a central release phenomenon
producing abnormal visual experiences, similar to that seen with
lesions elsewhere in the visual pathways.
31 The limbic structures
that appear important in the genesis of VH in PD and DLB
appear to be much less vulnerable to PSP tau and MSA synuclein
pathology than Lewy body pathology.
52 53 Unlike in advancing
PD, temporal lobe pathology is less common in PSP.
54 Although
low density nuclear inclusions are found in the subiculum and
dentate gyrus in MSA, there is little or no cell loss in the
amygdala and hippocampus.
53 55 It is worth noting, however,
that up to 10% of patients with pathological MSA may also
have Lewy bodies
5 and there are rare reports of temporal lobe
atrophy in patients with slow disease progression and long
disease duration.
55 These factors may be relevant in the emer-
gence of VH in the few reported cases of MSA.
WHAT IS THE ROLE OF VISUAL HALLUCINATIONS IN THE
DIFFERENTIAL DIAGNOSIS OF PARKINSONISM?
Given the high prevalence of VH in patients with Lewy body
pathologies, it is tempting to consider that their emergence and
development might, in some way, be due to neuronal dysfunc-
tion that is speciﬁct oa-synuclein protein accumulation. VH are
established as a diagnostic feature of DLB.
13 The prevalence of
450 J Neurol Neurosurg Psychiatry 2012;83:448e452. doi:10.1136/jnnp-2011-300980
Movement disordersVH in PD compared with other forms of parkinsonism argues
they should form part of the diagnostic criteria for PD also.
9
Although both DLB and PD are characterised by Lewy body
pathology, VH are signiﬁcantly more common and tend to
present earlier in DLB.
13 Of course, the major difference between
these conditions under the microscope is the distribution of the
Lewy body pathology. In both, Lewy body neurodegeneration
occurs in the brainstem and limbic structures but clinical
dementia correlates with neocortical Lewy body density
regardless of other clinical features.
29 It is in these patients that
VH are more likely to occur.
Therefore, as a clinical marker, VH are much more likely to
reﬂect the topographic distribution of pathology than charac-
teristics inherent to speciﬁc insoluble protein accumulations,
such as a-synuclein, or even b-amyloid or tau. In this light, VH
as a diagnostic feature of Lewy body pathology is limited by the
extent to which other pathologies affect the brain regions
important in the genesis of VH. Fortunately, most clinical and
pathological studies report a low frequency of VH in non-Lewy
body forms of Parkinsonism (see table 1), which we would
interpret as a low likelihood of these conditions affecting the
visual cortex, temporal cortex and other visual pathways. This
assumption is supported by the pathological data.
VH are reported in only 7% of patients with non-PD parkin-
sonism with conﬁrmed pathological diagnosis.
9 PSP is associated
with high rates of apathy and disinhibition but low rates of
hallucinations, even in the context of dopaminergic medication
use.
95 7Hallucinations have been reported to occur in 5e9% of
patients with MSA but rarely in CBD.
18 58 The presence of VH
at any stage over the course of the disease is strongly predictive
of Lewy body pathology and suggests this symptom may be
useful in determining diagnosis.
63
As an illustrative case, Compta et al described a patient with
clinical features of PD who was responsive to levodopa for some
years, and developed visual hallucinations late in the disease
course. Although the clinical diagnosis remained consistent with
PD, at autopsy she was found to have no synuclein or ubiquitin
staining, but widespread phosphorylated tau deposits consistent
with PSP, including severe pathology in the hippocampus and
amygdala.
64
Therefore, while the development of VH is very suggestive of
Lewy body pathology, it appears more likely that the location of
that pathology in the brain is the most important factor. The
speciﬁcity of VH for Lewy body pathology likely relates to the
higher frequency of involvement of the amygdala, visual and
temporal cortices in PD and DLB compared with the other
parkinsonian syndromes.
CONCLUSION
VH frequently occur later in the course of PD but are rarely
spontaneously reported by patients when mild. Direct ques-
tioning is often needed to identify VH, and they are more likely
to occur in patients who have cognitive disturbance, depression,
visual pathology and REM sleep behaviour disorder. Although
patients often maintain insight into the abnormal visual expe-
riences, hallucinations are not benign phenomena as they are
often not responsive to medical treatments and represent a risk
factor for nursing home placement and increased mortality. The
development of VH is the result of complex mechanisms inte-
grating visual input, processing and interpretation through
limbic and temporal regions. The differential expression of
hallucinations is likely related to the increased predilection for
Lewy body pathology to affect these brain regions and therefore,
in the appropriate clinical setting, the presence of VH should be
considered strongly suggestive of underlying Lewy body
pathology.
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